Latest revenue
—
as of 2025-12-31
Latest net income
$-166.3M
as of 2025-12-31
Net margin
—
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think AVBP is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.42B
- Enterprise value
- $1.35B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 4.37×
- Dividend yield
- 0.0%
- 52-wk high
- $33.62
- 52-wk low
- $16.10
- Beta
- —
- Shares out
- 46.6M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations You should read the following discussion and analysis of our financial condition and results of operations together with our interim financial statements and related notes appearing elsewhere in this Quarterly Report and the audited financial information and the notes thereto included in our Annual Report on Form 10-K for fiscal year ended December 31, 2025, which was filed with the SEC on March 5, 2026 (Annual Report). Some of the information contained in this discussion and analysis or set forth elsewhere, including information with respect to our plans and strategy for our business and related…
AI summary unavailable — showing raw filing excerpt
Generated from AVBP's filing dated 2026-05-11
Key risks
Item 1A. Risk Factors Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, the section of this Annual Report titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes appearing elsewhere in this Annual Report, before investing in our common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. If any of the following risks occur, our business,…
AI summary unavailable — showing raw filing excerpt
Generated from AVBP's filing dated 2026-05-11
Profitability
Return on equity
-54.1%
73.3%Return on assets
-49.9%
70.5%Leverage
Debt / equity
0.08×
25.9%Debt / assets
7.8%
23.8%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-43.3M | +32.7% | — |
Q4 2025 2025-12-31 | — | — | $-35.5M | -72.3% | — |
Q3 2025 2025-09-30 | — | — | $-35.0M | -70.1% | — |
Q2 2025 2025-06-30 | — | — | $-31.4M | -43.5% | — |
Q1 2025 2025-03-31 | — | — | $-64.4M | -269.7% | — |
Q4 2024 2024-12-31 | — | — | $-20.6M | — | — |
Q3 2024 2024-09-30 | — | — | $-20.6M | -42.8% | — |
Q2 2024 2024-06-30 | — | — | $-21.9M | -1.4% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on AVBP — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$13.0M
Net activity
−$13.0M
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| 2025-12-10 | HILLHOUSE INVESTMENT MANAGEMENT, LTD. / HHLR ADVISORS, LTD. 10%+ owner | Sale | 555,555 | $23.37 | $13.0M |
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AVBP
Institutional value
$136.5M
Total shares held
6.0M
Distinct holders
60
-62 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 2.5M | $58.4M | +157.5K (+6.6%) | Added |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1.5M | $35.3M | — | New |
| 3 | UBS Group AG | 486.3K | $11.2M | +35.3K (+7.8%) | Added |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 253.9K | $5.9M | — | New |
| 5 | VANGUARD FIDUCIARY TRUST CO | 217.1K | $5.0M | — | New |
| 6 | DIMENSIONAL FUND ADVISORS LP | 126.5K | $2.9M | +111.8K (+758.2%) | Added |
| 7 | E Fund Management Co., Ltd. | 94.0K | $2.2M | — | New |
| 8 | Bank of New York Mellon Corp | 75.4K | $1.7M | +2.3K (+3.2%) | Added |
| 9 | JPMORGAN CHASE & CO | 65.9K | $1.4M | -3.5K (-5.1%) | Trimmed |
| 10 | Nuveen, LLC | 56.8K | $1.3M | +3.2K (+6.0%) | Added |
| 11 | Moody Aldrich Partners LLC | 56.1K | $1.3M | -571 (-1.0%) | Trimmed |
| 12 | Swiss National Bank | 40.0K | $922.8K | +0 (+0.0%) | No change |
| 13 | ALPS ADVISORS INC | 36.0K | $830.2K | +2.1K (+6.2%) | Added |
| 14 | RHUMBLINE ADVISERS | 35.1K | $810.9K | +3.7K (+11.7%) | Added |
| 15 | DEUTSCHE BANK AG\ | 28.0K | $645.5K | +6.4K (+29.9%) | Added |
| 16 | Invesco Ltd. | 23.9K | $552.3K | +7.0K (+41.7%) | Added |
| 17 | Optimize Financial Inc | 18.9K | $436.4K | — | New |
| 18 | JANE STREET GROUP, LLC | 17.7K | $407.4K | -85.6K (-82.9%) | Trimmed |
| 19 | LOS ANGELES CAPITAL MANAGEMENT LLC | 17.3K | $399.3K | -23.0K (-57.1%) | Trimmed |
| 20 | PROFUND ADVISORS LLC | 16.8K | $387.9K | +5.8K (+53.1%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AVBP's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.